GlassScriptPhysician profile
Natalie Ellison
NPI 1881211043
$1,797.97
in general payments reported to CMS, 2019-2025
18 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $342 · 2023: $465 · 2024: $539 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.69 | 2021-2025 | |
| Novo Nordisk INC | $262.92 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $204.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $126.85 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.76 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.32 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $113.20 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $80.50 | 2022-2025 | Mounjaro, Jardiance |
| Amgen INC. | $57.82 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $55.04 | 2021-2025 | |
| Shield Therapeutics INC | $46.55 | 2025 | |
| Dexcom, INC. | $44.43 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $24.35 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.23 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $20.41 | 2024 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.84 | 2025 | Rexulti |
| Intra-Sana Laboratories | $10.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.